Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Hims & Hers Health, Inc. engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this conduct posed a significant risk of terminating the Company's collaboration with Novo Nordisk [2]. - The lawsuit asserts that the positive statements made by the defendants regarding the Company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements from the company could lead to the termination of its collaboration with Novo Nordisk [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment by August 25, 2025 [3]. - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices [4]. - The firm is dedicated to ensuring companies adhere to responsible business practices and good corporate citizenship [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [4].

Core Viewpoint - Hims & Hers Health is experiencing significant revenue growth and expanding its subscriber base, despite volatility in its stock price and challenges in the weight loss segment [1][4][6]. Financial Performance - In Q2, Hims & Hers reported a revenue increase of 73% year-over-year, reaching $544.8 million, which was at the high end of its forecast but below analyst expectations [4][10]. - Monthly online revenue per subscriber rose by 30% to $74, and the total number of subscribers increased by 31% to nearly 2.44 million [4][10]. - Adjusted EBITDA surged to $82.2 million, a 109% increase from the previous year, and adjusted EPS was $0.17, exceeding analyst expectations [8][10]. Subscriber Growth - The number of customers using at least one personalized subscription grew by 89% to 1.5 million, making up over 60% of the subscriber base [5]. - The company noted a 170% increase in subscribers using personalized treatment plans for multiple conditions, reaching over 500,000 [5]. Marketing and Expenses - Marketing expenses increased by 50% to nearly $218 million, accounting for 40% of revenue, down from 46% a year ago, indicating improved efficiency [7][10]. - The gross margin was reported at 76%, reflecting a decrease of 500 basis points year-over-year [10]. Future Outlook - Hims & Hers maintains its 2025 revenue forecast of $2.3 billion to $2.4 billion, representing growth of 56% to 63%, and adjusted EBITDA guidance of $295 million to $335 million [10][11]. - For Q3, the company projects revenue between $570 million and $590 million, with adjusted EBITDA of $60 million to $70 million [11]. - The company is planning international expansion, starting with Canada and targeting Europe, Latin America, and Asia in the coming years [11][12]. Growth Opportunities - Hims & Hers is expanding into new areas, including hormonal health, which is expected to contribute to its long-term revenue goals of $6.5 billion by 2030 [12]. - The company continues to see strong growth across various health categories, despite challenges in the weight loss segment [13]. Valuation - The stock trades at a forward P/E ratio of around 55 based on 2025 analyst estimates, with a PEG ratio under 0.6, indicating potential undervaluation [14]. - The price-to-sales multiple is 5.5 times 2025 estimates, suggesting reasonable pricing given the high gross margins of the subscription business [14].

Core Insights - Hims & Hers is experiencing rapid revenue growth but is currently facing a legal battle that poses risks to its future performance [1][4] - The company's stock has seen a significant decline of 17% this week and is down 25% from its all-time highs, despite a remarkable 400% increase over the past five years [1][2] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue growth, exceeding $500 million, driven by a 30% increase in total subscribers and a 30% rise in spending per active subscriber [2] - The company has achieved $2 billion in trailing revenue, marking an increase of over 1,000% in the last five years, solidifying its position as a leading telehealth provider [6] Legal Challenges - Hims & Hers is embroiled in a legal dispute with Novo Nordisk, stemming from allegations of selling knockoff weight loss drugs after a partnership ended due to disagreements [3][4] - The company is accused of illegally selling patented weight loss drugs at a discount now that the shortage has resolved, raising concerns among investors about the potential impact on future revenue and profitability [3][4] Market Position - Hims & Hers has made significant market share gains in the telehealth sector, particularly in the online provision of drugs and medical treatments [6] - Despite its strong growth trajectory, the ongoing legal issues may deter potential investors from buying the stock at its current dip [7][8]

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The complaint against Hims alleges violations of federal securities laws due to misleading statements and failure to disclose risks related to the sale of illegitimate drugs, leading to a significant drop in stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Allegations and Legal Actions - Hims is accused of engaging in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - The termination of the partnership with Novo Nordisk was attributed to Hims' failure to comply with legal standards regarding drug sales and marketing practices [3]. - Following the announcement of the partnership termination, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share [3]. Group 2: Class Action Details - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class has the option to move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3: Call for Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Hims' conduct, including whistleblowers and former employees, to come forward [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, which has led to a significant drop in its stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Sookdeo v. Hims & Hers Health, Inc. and covers the period from April 29, 2025, to June 23, 2025 [1]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding patient safety [2]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices, which resulted in a more than 34% decline in Hims & Hers stock price [3]. Group 2: Lead Plaintiff Process - Investors who purchased Hims & Hers securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [4]. - The lead plaintiff is typically the investor with the greatest financial interest and must be typical and adequate of the class [4]. Group 3: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Insights - Hims & Hers Health's stock has increased by approximately 24% since the last coverage, indicating positive market sentiment towards the company [1] - Following the announcement of the company's Q2'25 earnings report, there was a pre-market stock price drop, suggesting potential concerns among investors regarding the earnings results [1] Financial Performance - The Q2'25 earnings report is a significant event that has impacted the stock price, highlighting the importance of earnings announcements in influencing investor behavior [1] Market Sentiment - The surge in stock price prior to the earnings report reflects a bullish sentiment in the market, while the subsequent drop indicates a shift in investor confidence post-announcement [1]

Core Insights - LifeMD reported Q2 2025 financial results with revenue of $62.2 million, a 23% increase year-over-year, but $4.1 million below consensus estimates [1][5] - The company experienced a GAAP EPS loss of $0.06, which was also below analyst expectations by $0.0517 [1][5] - Despite strong telehealth growth and improved operational profitability, the company reduced its full-year guidance due to segment-specific pressures, particularly in men's health [1][15] Financial Performance - Revenue (GAAP) for Q2 2025 was $62.2 million, up from $50.7 million in Q2 2024, reflecting a 22.8% year-over-year increase [2] - Adjusted EBITDA rose to $7.1 million from $2.2 million in Q2 2024, marking a 223% increase [2] - Telehealth revenue reached $48.6 million, a 30% increase from $37.4 million in Q2 2024 [2] - Active telehealth subscribers grew to nearly 297,000, up 16% year-over-year [5] Business Model and Growth Factors - LifeMD focuses on subscription-based telehealth services for chronic condition management, primary care, and specialty health [3] - The company emphasizes recurring telehealth subscriptions and expansion into new clinical verticals such as behavioral and women's health [4] - Key growth drivers include regulatory compliance, patient retention, and strategic partnerships with healthcare brands [4] Segment Performance - The telehealth segment is the main growth engine, with Telehealth Adjusted EBITDA increasing 560% to $3.4 million [6] - WorkSimpli revenue edged up 3% year-over-year, but active subscribers fell 6% as the company shifted focus to higher-value clients [7] - Gross margin decreased to 88% from 90% in the previous year, attributed to changes in revenue mix [8] Strategic Initiatives - LifeMD launched a national behavioral health service and is rolling out subscription-based virtual women's health programs [11] - The company enhanced its LifeMD+ membership program to aggregate various health services for better patient retention [11] - Strategic partnerships with weight management drug providers aim to improve patient access to therapies [13] Guidance and Outlook - For Q3 2025, total revenue is projected between $61 million and $63 million, with telehealth revenue expected to be $48 million to $50 million [16] - Full-year guidance was lowered to $250–$255 million in total revenue and $27–$29 million in Adjusted EBITDA due to ongoing challenges [15][17] - The company's near-term performance will depend on stabilizing subscriber growth and successfully integrating new verticals [17]

Company Overview - LifeMD is building a leading platform for comprehensive virtual healthcare[7] - The company has conducted 13 million virtual consults and has 297000 active patients[8] - LifeMD's revenue guidance for 2025 is between $250 million and $255 million[8] - The company has over 300 employees across the US[8] Investment Highlights - LifeMD forecasts $27 million to $29 million of Adjusted EBITDA for 2025[12] - The company's products and services generate 85%+ consolidated gross margins[12] - WorkSimpli, in which LifeMD holds a 73% equity stake, provides high-margin recurring revenue[9, 12] Financial Performance and Guidance - LifeMD forecasts 20% revenue growth in 2025, with revenue reaching $255 million[42] - Telehealth revenue is projected to grow by 23% to 27%, reaching $195 million to $200 million in 2025[50] - WorkSimpli is expected to generate $55 million in revenue in 2025, a 2% increase[50] - Consolidated Adjusted EBITDA is projected to increase by 93% to 107%, reaching $27 million to $29 million in 2025[50]